IP Library › Granted Patent US 12,385,922
Granted Patent B2
US 12,385,922 · App. 17/203,832 · Granted Aug 12, 2025

Size-based gating to analyze flow cytometry data

Inventors: Nelson R. Alexander (Marana, AZ); Aoune Barhoumi (Oro Valley, AZ); Lisa L. Gallegos (Tucson, AZ)
Assignee: Ventana Medical Systems, Inc.
G01N33/57484G01N15/1429G01N15/1459G01N2015/1006G01N2015/1402
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,385,922
App. No.
17/203,832
Granted
Aug 12, 2025
Kind
B2
Abstract

Disclosed herein is a method of analyzing flow cytometry data for cells derived from homogenized whole tumor samples.

Claims (17)

1. A method of quantifying a percentage of cells expressing one or more biomarkers comprising:

obtaining a fixed surgical sample derived from a fixed residual surgical sample, a fixed biopsy sample, or a fixed histological sample;

mechanically shearing the obtained fixed surgical sample to provide a homogenized sample, wherein any heterogeneity of cells within the obtained fixed surgical sample is substantially uniformly distributed within the homogenized sample such that any aliquot removed from the homogenized sample expresses the heterogeneity of the fixed surgical sample;

staining the cells in the homogenized sample for the presence of the one or more biomarkers;

obtaining flow cytometry data based on the stained cells in the homogenized sample;

performing a first primary gating of the stained cells in the obtained flow cytometry data based on size and granularity scattering to provide a first population of cells having a first predicted cell type;

determining a percentage of cells expressing a first of the one or more biomarkers in a first sub-population within the first population of cells;

performing a second primary gating of the obtained flow cytometry data to provide at least a second population of cells having a second predicted cell type, and wherein the second predicted cell type are tumor cells;

determining a percentage of cells within the second population of cells having a chromosomal abnormality; and

correlating the determined percentage of cells having the chromosomal abnormality with the determined percentage of cells expressing the first of the one or more biomarkers.

2. The method of claim 1 , wherein the method does not require a physical sorting step prior to determining the percentage of cells expressing the first of the one or more biomarkers in the first sub-population within the first population of cells.

3. The method of claim 1 , wherein the first predicted cell type are immune cells, and wherein the immune cells have a size of less than about 12 μm.

4. The method of claim 3 , wherein the percentage of cells expressing the first of the one or more biomarkers in the first sub-population within the first population of cells is determined by performing a secondary gating of the cells in the first population based on the presence of the first of the one or more biomarkers.

5. The method of claim 4 , wherein the first of the one or more biomarkers is selected from the group consisting of a CD3, CD4, CD8, CD45RA, and CD45RO cluster of differentiation biomarker.

6. The method of claim 5 , further comprising determining a percentage of cells expressing a second of the one or more biomarkers in a second sub-population within the first population of cells, wherein the first and second of the one or more biomarkers are different.

7. The method of claim 6 , wherein the second of the one or more biomarkers is a cluster of differentiation marker selected from the group consisting of PD-1, TIM-3, LAG-3, CD28, CD57, and FOXP3.

8. The method of claim 6 , wherein the first of the one or more biomarkers is CD3, and wherein the second of the one or more biomarkers is a biomarker which differentiates the immune cells as regulatory, helper, or cytotoxic T cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: ALEXANDER, NELSON R.; BARHOUMI, AOUNE; GALLEGOS, LISA L.
To: VENTANA MEDICAL SYSTEMS, INC.
Reel/Frame 060101/0813 →
Continuity (3)
Continuation PCTEP2019074952 · Sep 18, 2019
Provisional Application 62733829 · Sep 20, 2018
Related Publication 20210270837A1 · Sep 2, 2021
References Cited (35)
US 6767737B1 · Wilson · 2004 [cited by examiner]
US 9910039B2 · Garcia Santana · 2018 [cited by applicant]
US 10782298B2 · Patterson et al. · 2020 [cited by applicant]
US 11959838B2 · Alexander et al. · 2024 [cited by applicant]
US 20140349313A1 · Balderas et al. · 2014 [cited by applicant]
US 20150337384A1 · Bartunkova et al. · 2015 [cited by applicant]
US 20160123980A1 · Evans et al. · 2016 [cited by applicant]
US 20180136214A1 · Patterson et al. · 2018 [cited by applicant]
US 20180252708A1 · De · 2018 [cited by applicant]
US 20180356420A1 · Volovitz et al. · 2018 [cited by applicant]
US 20200049599A1 · Alexander et al. · 2020 [cited by applicant]
US 20230065632A1 · Volovitz et al. · 2023 [cited by applicant]
CN 103782173A · 2014 [cited by applicant]
CN 105378066A · 2016 [cited by applicant]
CN 108449995A · 2018 [cited by applicant]
JP 2015526709A · 2015 [cited by applicant]
JP WO2018016656A1 · 2019 [cited by applicant]
WO 2017079763A1 · 2017 [cited by applicant]
WO 2017094008A1 · 2017 [cited by applicant]
WO 2018016656A1 · 2018 [cited by applicant]
WO 2018048936A1 · 2018 [cited by applicant]
Cano et al (Autoimmunity: From Bench to Bedside, Chapter 5 Introduction to T and B lymphocytes, El Rosario University Press, Jul. 18, 2013). [cited by examiner]
Rathore et al (Indian J Med Res, 2014, 140: 361-369). [cited by examiner]
Daniil et al (Respiratory Research, 2005, 6(81): 1-8). [cited by examiner]
Grange et al (Journal of Immunological Methods, 2011, 372: 119-126). [cited by examiner]
Givan (Flow Cytometry Protocols, Third Edition, Humana Press, 2011, Chapter 1, “Flow Cytometry: An Introduction”, pp. 1-29). [cited by examiner]
Turksma et al (Clinical Cancer Research, 2016, 22(2): 346-356). [cited by examiner]
Hristov et al (Cytometry Part A, 2009, 775A: 848-853). [cited by examiner]
Hao et al (Advanced Drug Delivery, 2018, 125: 3-20). [cited by examiner]
Strokotov et al (Journal of Biomedical Optics, 2009, 14(6): 1-12). [cited by examiner]
International Search Report and Written Opinion, dated Feb. 1, 2020. [cited by applicant]
Karolina Woroniecka et al, “Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma : Methods and Protocols”, “Methods in Molecular Biology”, p. 221-226, Jan. 1, 2018 (Jan. 1, 2018), US Humana… [cited by applicant]
Magdalena Kovacsovics-Bankowski et al, “Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities”, Journal for Immunotherapy of Cancer, 33rd Annua… [cited by applicant]
A. Richter et al, “Tumor infiltrating T cells: complete workflows allow faster and improved flow cytometric analysis of syngeneic mouse tumors,” Jul. 2, 2018 (Jul. 2, 2018), DOI: 10.1158-7445,AM2018-LB-351. [cited by applicant]
Santegoets Saskia J et al, “Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry”, Jun. 28, 2015 (Jun. 28, 2015), v… [cited by applicant]